Latest News and Press Releases

Intrommune welcomes an independent editorial that was recently published in Annals of Allergy, Asthma & Immunology.

Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy

Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...

Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...

NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...

NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...

NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...